Figure 7
Effects of chronic pretreatment with celecoxib (6000 ppm for 6 weeks) on LPS-induced brain IL-1β levels, the expression of COX-1, p67phox NADPH oxidase subunit and the phosphorylated STAT3. (A) Representative immunoblot of COX-1 protein levels, relative to GAPDH internal loading control, in the whole brain of COX-2+/+ and celecoxib-treated COX-2+/+ mice 24 h after icv injection of LPS or vehicle. (B) ELISA based immunoassay for brain IL-1β in celecoxib-treated mice (n = 7) and untreated COX-2+/+ mice (n = 4). (C) Quantification of p67phox protein levels, relative to GAPDH internal loading control in the whole brain with representative immunoblot (D) in celecoxib-treated mice and untreated COX-2+/+ mice (n = 4). (E) Quantification of phosphorylated STAT3 (Tyr 705) protein levels, relative to the total STAT3 in the brain nuclear fraction and the representative immunoblot (F) in celecoxib-treated mice and untreated COX-2+/+ mice (n = 4). All data are expressed as mean ± SEM. *P <0.05, **P < 0.01, ***P < 0.001 compared to the corresponding vehicle-injected mice; #P < 0.05, ###P < 0.001 compared to the LPS-injected COX-2+/+ mice.